Aegis Capital initiated coverage on PharmAthene (NYSE: PIP ) with a Buy rating and a $6.00 price target. Aegis Capital commented, "We believe that PharmAthene's current enterprise value of roughly $50mm neither gives adequate credit to the company's own proprietary pipeline nor appropriately values the potential for significant revenues from